Location:

• Nucleus Network in Herston, Queensland
• Melbourne, Victoria

Participants:

• 131 healthy adults
• see child node for more details

Randomized, placebo-control, phase 1-2 trial:

• 5 ug and 25 ug doses with and without Matrix M1 adjuvant
• Phase 1: two intramuscular injections, 21 days apart

Procedure:

• rSARS-CoV-2 and Matrix M1 mixed before injection
• each participant received 2 intramuscular injections of trail vaccine or the placebo in the deltoid muscle

Safety Outcomes:

• Reactogenicity: track days 0 to 7 and days 21 to 28
• Laboratory values: day 21, and unsolicited adverse events during the first 35 days
• participants also had nasopharyngeal swab testing for SARS-CoV-2 on day 35 or when they reported symptoms
• after each vaccination, participants were observed for at least 30 minutes after